Ultra-processed foods and CKD: a review of evidence, limitations, and future directions [0.03%]
超加工食品与慢性肾病：证据、局限性及未来研究方向综述
Giulia Barbieri,Cristina Valle-Hita,Essi Hantikainen
Giulia Barbieri
Purpose of review: To critically examine the emerging evidence linking ultra-processed food (UPF) consumption to chronic kidney disease (CKD), with a particular focus on prevention strategies, biological mechanisms, and i...
The current landscape of prospective proteomics research into dementia using blood-based samples [0.03%]
基于血液样本的痴呆症蛋白组学研究现状与前景展望
Josefine Tvermoes Meineche,Michael Wierer,Majken Karoline Jensen
Josefine Tvermoes Meineche
Purpose of review: Well conducted, prospective, blood-based biomarker studies on dementia risk are growing, providing valuable insights into disease mechanisms that precede clinical symptoms. These investigations are cruc...
Inflammation and atherosclerotic cardiovascular disease: where do we go from here? [0.03%]
炎症与动脉粥样硬化性心血管疾病：未来研究展望
Ori Waksman,Ron Waksman
Ori Waksman
Purpose of review: Low-grade systemic inflammation, as determined by high-sensitivity C-Reactive Protein (hsCRP), plays a significant role in the progression and development of atherosclerotic cardiovascular disease (ASCV...
Angela Pirillo,Alberico L Catapano
Angela Pirillo
Purpose of review: The causal role of LDL in atherosclerotic cardiovascular disease (ASCVD) is well established, but the contribution of HDL has proven more complex. CETP inhibitors were originally developed to increase H...
Michael B Boffa,Marlys L Koschinsky,Robert A Hegele
Michael B Boffa
Purpose of review: Elevated plasma lipoprotein(a) [Lp(a)] is a causal and independent risk factor for atherosclerotic cardiovascular disease and an emerging therapeutic target. Over the past 15 years, many medical bodies ...
Future of angiopoietin-like protein 3 inhibitors as a therapeutic agent [0.03%]
angiopoietin-like蛋白3抑制剂的治疗作用及发展前景
Nicholas A Marston,André Zimerman
Nicholas A Marston
Purpose of review: Triglyceride-rich lipoproteins (TRLs) and LDL remain major drivers of atherosclerotic cardiovascular disease, and angiopoietin-like protein 3 (ANGPTL3) has emerged as a promising target to lower both tr...
Harnessing dysglycaemia heterogeneity for precision type 2 diabetes prevention [0.03%]
利用糖尿病异质性精准预防2型糖尿病
Suyi Xie,Jordi Merino
Suyi Xie
Purpose of review: Type 2 diabetes (T2D) is a heterogeneous, progressive metabolic disease and a major contributor to cardiovascular disease worldwide. Current prevention strategies, centred on population-level lifestyle ...
Macrophage cannibalism: efferocytosis in atherosclerosis [0.03%]
巨噬细胞食胞作用在动脉粥样硬化中的作用机制研究-Efferocytosis in Atherosclerosis
Amy A Baxter,Ivan K H Poon,Denuja Karunakaran
Amy A Baxter
Purpose of review: This review explores the evolving understanding of efferocytosis - the clearance of dead or dying cells by phagocytes - in the context of atherosclerosis. It highlights recent discovers in cell death mo...
Timo E Strandberg
Timo E Strandberg
Purpose of review: In 1994, the 4S trial was revolutionary by showing that cholesterol lowering with simvastatin reduced, not only atherosclerotic vascular disease (ASCVD) events, but also all-cause mortality as compared ...